<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04050436</url>
  </required_header>
  <id_info>
    <org_study_id>RPL-002-18</org_study_id>
    <nct_id>NCT04050436</nct_id>
  </id_info>
  <brief_title>Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer</brief_title>
  <acronym>CERPASS</acronym>
  <official_title>A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Replimune Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Replimune Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination
      with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall
      response rate (ORR) according to central review.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2019</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 according to central review</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR for patients with metastatic or locally advanced disease</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR for patients who have and have not previously received systemic CSCC-directed therapy</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR by investigator assessment</measure>
    <time_frame>approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of individual tumor response in injected versus non-injected lesions</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR) per central and investigator review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS) per central and investigator review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response (CR) rate per central and investigator review</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>approximately 36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety and tolerability of cemiplimab alone and combined with RP1 as assessed via adverse events (AEs)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall adverse event rates and adverse event rates per observation period will be compared for the two treatment groups using a two-sided Fisher Exact test. Results will be analyzed by SOC and for preferred terms with &gt;10% overall incidence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in overall scores of patient-reported outcomes in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Cutaneous Squamous Cell Carcinoma</condition>
  <condition>Advanced Cutaneous Squamous Cell Carcinoma</condition>
  <condition>Metastatic Cutaneous Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cemiplimab in combination with RP1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cemiplimab administered intravenously every 3 weeks in combination with RP1 administered as an intratumoral injection every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cemiplimab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cemiplimab administered intravenously as a single therapy every 3 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cemiplimab</intervention_name>
    <description>Cemiplimab administered intravenously</description>
    <arm_group_label>Cemiplimab</arm_group_label>
    <arm_group_label>Cemiplimab in combination with RP1</arm_group_label>
    <other_name>Libtayo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RP1</intervention_name>
    <description>RP1 administered intratumorally</description>
    <arm_group_label>Cemiplimab in combination with RP1</arm_group_label>
    <other_name>Genetically modified herpes simplex type 1 virus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Histologically confirmed locally advanced or metastatic cutaneous squamous cell
             carcinoma

          -  Patients for whom surgical or radiological treatment of lesions is contraindicated

          -  At least 1 lesion that is measurable and injectable by study criteria (tumor of ≥1cm
             in longest diameter or ≥1.5 cm in shortest diameter for lymph nodes).

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤1

          -  Anticipated life expectancy &gt;12 weeks

          -  All patients must consent to provide archived or newly obtained tumor material for
             central pathology review for confirmation of diagnosis of CSCC.

        Key Exclusion Criteria:

          -  Prior treatment with an oncolytic therapy

          -  Patients with active significant herpetic infections or prior complications of HSV-1
             infection (e.g. herpetic keratitis or encephalitis)

          -  Patients who require intermittent or chronic use of systemic (oral or intravenous)
             anti-virals with known anti-herpetic activity (e.g. acyclovir)

          -  Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
             required treatment with systemic immunosuppressive treatments

          -  Prior treatment with an agent that blocks the PD-1/PD-L1 pathway.

          -  Prior treatment with other immune modulating agents other than as adjuvant or
             neoadjuvant therapy.

          -  Untreated brain metastasis(es) that may be considered active.

          -  Known infection including active infection with hepatitis B virus (HBV), hepatitis C
             virus (HCV) or human immunodeficiency virus (HIV).

          -  History of ILD/pneumonitis within the last 5 years or a history of ILD/pneumonitis
             requiring treatment with systemic steroids.

        Note: Other protocol defined Inclusion/Exclusion criteria apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selda Samakoglu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Senior Medical Director</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>CERPASS Study</last_name>
    <phone>781 222-9540</phone>
    <email>CERPASS@replimune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Badri Modi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chan Soon-Shiong Institute for Medicine</name>
      <address>
        <city>El Segundo</city>
        <state>California</state>
        <zip>90245</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara Seery, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mina Nikanjam, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanxing Chai-Ho, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl Lewis, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Health System</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Lutzky, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ragini Kudchadkar, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Silk, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rekha Chaudhary, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rom Leidner, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Lee, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Medical Day Care Centre</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Brungs, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tasman Oncology Research Ltd</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Hill, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhammad Alamgeer, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Centre</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danny Rischin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Alfred</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Haydon, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 2, 2019</study_first_submitted>
  <study_first_submitted_qc>August 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2019</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oncolytic Virus</keyword>
  <keyword>Carcinoma</keyword>
  <keyword>Carcinoma, Squamous Cell</keyword>
  <keyword>Cemiplimab</keyword>
  <keyword>Metastatic Cutaneous Squamous Cell Carcinoma</keyword>
  <keyword>Oncolytic Immuno-gene therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

